Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;11(Suppl 3):S396-S398.
doi: 10.21037/jtd.2018.11.140.

PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!

Paul Hofman  1   2   3
Affiliations
Editorial

PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!

Paul Hofman. J Thorac Dis. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: P Hofman is a member of different industrial scientific advisory boards (Roche, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Merck, MSD, Qiagen, Thermofischer, Biocartis) for which he receives honorarium.

Comment on

References

    1. Brower V. Hyperprogressive disease with anti-PD-1 and anti-PD-L1. Lancet Oncol 2016;17:e527. 10.1016/S1470-2045(16)30590-3 - DOI - PubMed
    1. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920-8. 10.1158/1078-0432.CCR-16-1741 - DOI - PubMed
    1. Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018;15:748-62. 10.1038/s41571-018-0111-2 - DOI - PubMed
    1. Fuentes-Antrás J, Provencio M, Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev 2018;70:16-21. 10.1016/j.ctrv.2018.07.006 - DOI - PubMed
    1. Kurman JS, Murgu SD. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. J Thorac Dis 2018;10:1124-8. 10.21037/jtd.2018.01.79 - DOI - PMC - PubMed